HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

752.766

-36.796-4.66%

Number of Gainers:6

Number of Losers:27

Number of Flat:1

PE:- -

High:790.354

Open:789.588

Low:747.423

Close:789.562

Loading ...

NH HEALTH (06606): Joint Provisional Liquidators Application Filed, Trading Suspension Continues

New Horizon Health Ltd. Applies for Joint Provisional Liquidators to Protect Shareholder Interests Amid Trading Suspension

AH Statistics | August 1st

UBS Reiterates "Buy" Rating on AKESO (09926), Raises Target Price to HK$197.5

A-Share Market Review: Trading Volume Shrinks by Over 300 Billion Yuan, Three Major Indices Close Slightly Lower While Pharmaceutical Stocks Maintain Strength

112% Returns at Peak Before Sudden Departure? Yongying Fund's Chu Kefan Resignation Sparks Speculation as "Steady Innovation" Strategy Shows Success Only in Healthcare

CARsgen Therapeutics Holdings Ltd. Announces Upcoming Board Meeting to Review Interim Results

Kintor Pharmaceutical Ltd. Announces Top-Up Placing and New Share Subscription Under General Mandate

BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per Share

Kintor Pharmaceutical - to Issue 20.7 Mln Shares for HK$2.08 per Share

THOMSON REUTERS

Kintor Pharmaceutical Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China

BRIEF-Alphamab Oncology's JSKN003 Receives FDA Approval

Zhaoke Secures US FDA Orphan Drug Status for Pediatric Eye Cancer Drug; Shares Lose 1%

MT Newswires Live

Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer

Alphamab Oncology - Jskn003 Receives FDA Approval for Phase Ii Clinical Study

THOMSON REUTERS

Akeso Inc. Announces Launch of Phase III Clinical Trial for Ivonescimab in Treatment of IO-Resistant NSCLC

Akeso Announces Completion of First Dosing in Phase Iii Clinical Trial of Ivonescimab (Pd-1/Vegf) Combination Therapy for Immunotherapy-Resistant Nsclc

THOMSON REUTERS

Ocumension Therapeutics' (HKG:1477) Shift From Loss To Profit

Simply Wall St.

Zhaoke Ophthalmology Ltd. Receives FDA Orphan Drug Designation for Melphalan Targeting Pediatric Retinoblastoma

Zhaoke Ophthalmology - US FDA Grants Orphan Drug Designation to Zhaoke's Melphalan

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":752.76556,"timestamp":1754554087272,"preClose":789.5618,"halted":0,"volume":192391393,"delay":0,"changeRate":-0.046603,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-36.796265,"latestTime":"08-07 16:00:00","open":789.58777,"high":790.3539,"low":747.4229,"amount":5475279379,"amplitude":0.054373,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754616600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1754530200000,1754539200000],[1754542800000,1754553600000]],"pbRate":6.386386,"peRate":-39.332742,"turnoverRate":0.007184,"increases":5,"decrements":28,"flats":0,"marketCap":442420526528,"floatMarketCap":409364985856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":790.3539,"amplitude":0.054373,"preClose":789.5618,"low":747.4229,"pbRate":"6.386386","latestPrice":752.76556,"volume":192391393,"delay":0,"open":789.58777,"prevYearClose":331.1933,"prevWeekClose":721.922,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":735.033,"twentyDayClose":596.151,"sixtyDayClose":449.306,"secType":"PLATE","market":"HK","turnoverRate":0.007184,"peRate":-39.332742,"marketCap":442420526528,"floatMarketCap":409364985856,"timestamp":1754554087272,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":27,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1144561776","title":"NH HEALTH (06606): Joint Provisional Liquidators Application Filed, Trading Suspension Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=1144561776","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144561776?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:54","pubTimestamp":1754038467,"startTime":"0","endTime":"0","summary":"NH HEALTH (06606) announced that the company formally filed an application and petition for joint provisional liquidators with the Grand Court on July 8, 2025 (Cayman time). The hearing for the joint...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","BK1574","06606"],"gpt_icon":0},{"id":"2556779893","title":"New Horizon Health Ltd. Applies for Joint Provisional Liquidators to Protect Shareholder Interests Amid Trading Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2556779893","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556779893?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:51","pubTimestamp":1754038285,"startTime":"0","endTime":"0","summary":"New Horizon Health Ltd. has filed an application for the appointment of joint provisional liquidators  with the Grand Court, scheduled for a hearing on August 6, 2025. This step aims to transfer the company's business and affairs to independent professional court officers to safeguard shareholder interests. The JPLs, if appointed, will investigate issues highlighted in previous announcements and explore potential restructuring options. Trading of the company's shares remains suspended since March 28, 2024, pending further updates. Shareholders and investors are advised to exercise caution when dealing with the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Horizon Health Ltd. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2Chf6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1219","06606"],"gpt_icon":0},{"id":"1150553590","title":"AH Statistics | August 1st","url":"https://stock-news.laohu8.com/highlight/detail?id=1150553590","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150553590?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:16","pubTimestamp":1754036212,"startTime":"0","endTime":"0","summary":"As of the close on August 1st, NE ELECTRIC (00042), HOLLY FUTURES (03678), and ANDRE JUICE (02218) ranked as the top three in AH premium rates, with premium rates of 800.00%, 237.59%, and 222.93%...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","LU2153592121.USD","LU0594300179.USD","LU0269904917.USD","LU0254981946.USD","02218","SG9999012744.USD","LU0501845795.SGD","SG9999002828.SGD","IE00BF5LJ272.USD","LU0488056044.USD","LU2294711713.HKD","81211","LU0348788117.USD","01288","BK1546","BK1594","LU0359202008.SGD","LU1880383366.USD","IE00B543WZ88.USD","LU1504937902.USD","LU0417516738.SGD","LU1831875114.USD","BK1509","LU2097828714.EUR","LU0345780281.USD","LU0979878070.USD","LU0061477393.USD","159982","SG9999015978.USD","LU1720050803.USD","LU0289961442.SGD","LU0449515922.USD","HK0000320223.HKD","LU0589944569.HKD","LU0043850808.USD","IE00BVYPNP33.GBP","LU0348816934.USD","LU0084288322.USD","LU0164872284.USD","LU0540923850.HKD","BK1240","LU0918141887.USD","LU0417516902.SGD","LU2348774022.SGD","LU0605514214.HKD","LU0918141705.HKD","01057","LU2360107325.USD","00187","01349","BK1205","00323","BK1141","BK1149","LU0052750758.USD","BYDDY","LU1282649141.HKD","LU0588545904.SGD","01375","LU1719994722.HKD","02039","IE00BMCWC346.EUR","SG9999012728.SGD","LU0326950275.SGD","LU1328277881.USD","LU0048580855.USD","LU0880133367.SGD","HK0000306685.HKD","IE00BZ08YS42.EUR","SG9999012710.SGD","BK1550","IE00BZ08YT58.USD","LU0823426480.USD","02238","LU1242518931.SGD","BK1505","BK1583","LU1048596156.SGD","BK1539","LU0819123356.HKD","LU1303224171.USD","LU1808992512.USD","LU0096374516.USD","01456","002594","BK1522","BK1147","02899","BK1582","HK0000306701.USD","LU0823038988.USD","BK1592","IE0008369823.USD","06185","LU0051755006.USD","LU0593848301.USD","IE00B3M56506.USD","LU0181495838.USD","LU0543330566.HKD","LU1188198961.HKD","LU0516422440.USD","LU0244354667.USD","LU1813983027.USD","IE00BVYPNQ40.USD","LU0886674414.USD","LU1224709979.USD","LU0502904849.HKD","LU0143863784.USD","SG9999014674.SGD","LU0516423091.SGD","LU0320764599.SGD","BK1198","LU0588546209.SGD","BK1584","LU0307460666.USD","LU0315178854.USD","LU1251922891.USD","02628","LU1688375341.USD","IE00B0169L03.USD","LU0348814723.USD","BK1515","06680","BK1514","LU0823039010.USD","LU0868486357.SGD","03678","LU0345780521.USD","LU1115378108.SGD","LU0359201612.USD","LU0384037296.USD","IE00B5MMRT66.SGD","03606","LU1961090484.USD","LU0516423174.USD","BK1551","LU0823426308.USD","BK1183","LU0348735423.USD","LU0106959298.USD","LU0289739343.SGD","LU1770034418.SGD","LU1880383440.USD","BK1529","LU0231483743.USD","BK1568","LU0890818403.SGD","LU0588545490.SGD","LU0327786744.USD","HK0000320264.USD","LU0314109678.HKD","LU1655091616.SGD","BK1116","LU2097828557.USD","LU0505663152.USD","IE0032431581.USD","SG9999002463.SGD","LU1023057109.AUD","LU1960683339.HKD","LU0634319403.HKD","LU1282649067.USD","LU2242644610.SGD","LU2249611893.SGD","LU1861219969.SGD","BK1607","SG9999001226.SGD","LU0287142896.SGD","03968","LU1211504680.USD","01211","LU0640798160.USD","HYDD.SI","BK1576","SG9999004220.SGD","LU0348825331.USD","SG9999012736.USD","LU1868838027.USD","LU0039217434.USD","BK1507","LU0456846285.SGD","LU2097828805.USD","LU0650527681.SGD","LU0648948544.HKD","LU1993786604.SGD","BK1521","LU0143863198.USD","LU0561508036.HKD","LU0469268626.HKD","BK1191","LU1226287529.USD","LU0819121731.USD","IE00BGHQDM52.EUR","06178","LU2097828474.EUR","BK1610","LU0862451753.SGD","00763","00042","03143","01812","02359","LU0823414478.USD","BK1554","00991","LU0259732245.USD","03750","IE00BZ08YR35.GBP","02727","LU0828238088.HKD","LU2045819591.USD","LU0214875030.USD","BK1171","LU0370786039.SGD","BK1237","LU2399975544.HKD","LU1152091754.HKD","BK1202","LU2449936058.SGD","LU0531970944.HKD","LU2506951792.HKD","IE00B031HY20.USD","02611","LU0828237940.HKD","LU1807302812.USD","IE0034224299.USD","LU1282649810.SGD","LU0865486749.SGD","LU0456827905.SGD","LU0173614495.USD","BK1225","BK1562","LU0449509016.USD","LU0289960550.SGD","LU0828237510.HKD","LU0229945570.USD","LU1868837565.USD","LU1152091168.USD","LU1282648689.USD","BK1544","LU0856984785.SGD","01033","BK1223","BK1144","LU1242518857.USD","SG9999015952.SGD","00300","399300","BK1161","LU2357125470.USD","LU0165289439.USD","LU2125910500.SGD","LU0072913022.USD","BK1560","LU0572944931.SGD","BK1564","LU0797268264.HKD","06127","LU0067412154.USD","LU0708995583.HKD","BK1119","LU0163747925.USD","IE00B031J352.USD","LU1861214812.USD","IE00BD6J9T35.USD","BK1506","BK1530","LU0531971595.HKD","IE00B29SXG58.USD","LU0871576103.HKD","BK1214","LU0315179316.USD","LU0348805143.USD","LU0463099449.HKD","LU0509642566.USD","LU1794554557.SGD","LU0054450605.USD","LU0140636845.USD","SG9999006514.SGD","00588","LU0164865239.USD","IE00BYV24P56.USD","IE0008368742.USD","BK1540","LU2778985437.USD","LU0431992006.USD","LU2226246903.HKD","LU1868837722.USD","IE0031814852.USD","BK1125","LU0594300419.USD","LU2097828631.EUR","SG9999015986.USD","SG9999006597.SGD","LU1675838814.USD","LU0359201885.HKD","LU0516422366.SGD","BK1184","SG9999015945.SGD","LU0211977185.USD","LU0516422952.EUR","BK1574","01276","BK1526","LU0175139822.USD","LU2476274308.USD","BK1231","LU0228659784.USD","LU1046422090.SGD","LU0348827113.USD","02338","LU2476274720.SGD","LU2039709279.SGD","LU1105468828.SGD","LU0588545730.USD","LU0511384066.AUD","LU0823414551.USD","LU0228367735.SGD","LU1008478684.HKD","LU0737861699.HKD","LU0821914370.USD"],"gpt_icon":1},{"id":"1106536074","title":"UBS Reiterates \"Buy\" Rating on AKESO (09926), Raises Target Price to HK$197.5","url":"https://stock-news.laohu8.com/highlight/detail?id=1106536074","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106536074?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:04","pubTimestamp":1754035461,"startTime":"0","endTime":"0","summary":"UBS released a research report stating that AKESO's (09926) core product AK112 (ivonescimab) demonstrates significant potential in indications beyond non-small cell lung cancer (NSCLC). In addition...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU1794554557.SGD","LU0348783233.USD","IE00B543WZ88.USD","BK1574","LU1720050803.USD","LU0348784397.USD","LU0417516571.SGD","BK1161","IE00BPRC5H50.USD","LU2488822045.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"1148385745","title":"A-Share Market Review: Trading Volume Shrinks by Over 300 Billion Yuan, Three Major Indices Close Slightly Lower While Pharmaceutical Stocks Maintain Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=1148385745","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148385745?lang=en_us&edition=fundamental","pubTime":"2025-08-01 15:30","pubTimestamp":1754033444,"startTime":"0","endTime":"0","summary":"On August 1st, A-shares adjusted on reduced trading volume with micro-cap stocks rising again. Over 3,300 stocks closed in the green, with total daily trading volume reaching 1.6 trillion yuan,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","159938","399300","BK1515","09939","159982"],"gpt_icon":0},{"id":"1147355320","title":"112% Returns at Peak Before Sudden Departure? Yongying Fund's Chu Kefan Resignation Sparks Speculation as \"Steady Innovation\" Strategy Shows Success Only in Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=1147355320","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147355320?lang=en_us&edition=fundamental","pubTime":"2025-08-01 15:21","pubTimestamp":1754032872,"startTime":"0","endTime":"0","summary":"The summer season's public fund personnel changes often reflect the subtle shifts in industry dynamics. In 2025, healthcare-themed funds have emerged as market leaders with accumulated momentum, with...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","159938","BK1161","09939"],"gpt_icon":0},{"id":"2556666458","title":"CARsgen Therapeutics Holdings Ltd. Announces Upcoming Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2556666458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556666458?lang=en_us&edition=fundamental","pubTime":"2025-08-01 12:05","pubTimestamp":1754021116,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Ltd. has announced that a board meeting will be held on Thursday, August 14, 2025. The purpose of the meeting is to consider and approve the interim results of the Group for the six months ended June 30, 2025, and to transact any other business.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL6DtRdt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","02171","BK1161","BK1585"],"gpt_icon":0},{"id":"2556851688","title":"Kintor Pharmaceutical Ltd. Announces Top-Up Placing and New Share Subscription Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851688","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851688?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:13","pubTimestamp":1754000009,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Limited has announced a top-up placing of existing shares and a subscription of new shares under a general mandate. The company, along with Dr. Tong and the Vendor, has entered into an agreement with a Placing Agent. Under this agreement, the Vendor will sell, and the Placing Agent will procure purchasers to buy, on a best effort basis, 20,673,000 shares at a price of HK$2.08 per share. This represents approximately 4.62% of the company's issued share capital. Dr. Youzhi Tong, Chairman of the Board, Executive Director, and CEO of Kintor Pharmaceutical, is overseeing the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL4x4nvw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2556485151","title":"BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556485151","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556485151?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:11","pubTimestamp":1753999890,"startTime":"0","endTime":"0","summary":"BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per ShareAug 1 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK:TO ISSUE 20.7 MILLION SHARES FOR HK$2.08 PER SHAREFurther company coverage: 9939.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS3G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2556851531","title":"Kintor Pharmaceutical -  to Issue 20.7 Mln Shares for HK$2.08 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851531","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851531?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:10","pubTimestamp":1753999844,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS3G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2555000050","title":"Kintor Pharmaceutical Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2555000050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555000050?lang=en_us&edition=fundamental","pubTime":"2025-07-31 17:08","pubTimestamp":1753952938,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia  in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL1ywmpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2555009209","title":"BRIEF-Alphamab Oncology's JSKN003 Receives FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2555009209","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555009209?lang=en_us&edition=fundamental","pubTime":"2025-07-31 15:00","pubTimestamp":1753945252,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology's JSKN003 Receives FDA ApprovalJuly 31 (Reuters) - Alphamab Oncology 9966.HK:JSKN003 RECEIVES FDA APPROVAL FOR PHASE II CLINICAL STUDYFurther company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TR2C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2555907061","title":"Zhaoke Secures US FDA Orphan Drug Status for Pediatric Eye Cancer Drug; Shares Lose 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555907061","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555907061?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:41","pubTimestamp":1753936915,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  said its proprietary formulation of melphalan has received orphan drug designation from the US Food and Drug Administration for the treatment of pediatric retinoblastoma, according to a Wednesday bourse filing.Shares of the company declined by over 1% in Thursday's recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1574","BK1587","06622","BK1191"],"gpt_icon":0},{"id":"2555771930","title":"Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2555771930","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555771930?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:07","pubTimestamp":1753934867,"startTime":"0","endTime":"0","summary":"Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer. Alphamab Oncology, a leading biopharmaceutical company in China, has received approval from the U.S. Food and Drug Administration  to initiate a Phase II clinical study for its drug candidate, JSKN003. This study, identified as JSKN003-202, will focus on the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, collectively known as platinum-resistant ovarian cancer . The study will be randomized, open-label, and multi-center. This advancement highlights Alphamab Oncology's proprietary protein engineering expertise and commitment to developing next-generation biological drug candidates. The company has not specified any collaboration with other organizations regarding this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative ar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL67kdfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2555077591","title":"Alphamab Oncology - Jskn003 Receives FDA Approval for Phase Ii Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555077591?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:00","pubTimestamp":1753934450,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TR2C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2555607999","title":"Akeso Inc. Announces Launch of Phase III Clinical Trial for Ivonescimab in Treatment of IO-Resistant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2555607999","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555607999?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:47","pubTimestamp":1753926439,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced the initiation of a Phase III clinical trial involving ivonescimab, a PD-1/VEGF bispecific antibody, in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer  that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. This pivotal study, AK112-305/HARMONi-8A, recently dosed its first patient. Ivonescimab is notable for being the only bispecific immunotherapy antibody currently in Phase III registration trials for immunotherapy-resistant lung cancer. The trial aims to provide a novel treatment option for patients with IO-resistant NSCLC, leveraging the synergistic effects of targeting both PD-1 and VEGF pathways to reactivate anti-tumor immune responses. The results of this ongoing study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL75mxhk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","09926","LU2488822045.USD","IE00B5MMRT66.SGD","LU0348783233.USD","BK1161","LU0417516571.SGD","LU0348784397.USD","BK1574","LU1720050803.USD"],"gpt_icon":0},{"id":"2555079964","title":"Akeso Announces Completion of First Dosing in Phase Iii Clinical Trial of Ivonescimab (Pd-1/Vegf) Combination  Therapy for Immunotherapy-Resistant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2555079964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555079964?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:47","pubTimestamp":1753926424,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA4Y6W9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","LU0348783233.USD","LU0348784397.USD","BK1161","IE00B543WZ88.USD","BK1574","LU1720050803.USD","IE00B5MMRT66.SGD","09926","LU1794554557.SGD","LU0417516571.SGD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2555207447","title":"Ocumension Therapeutics' (HKG:1477) Shift From Loss To Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2555207447","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555207447?lang=en_us&edition=fundamental","pubTime":"2025-07-31 07:58","pubTimestamp":1753919938,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Ocumension Therapeutics' ( HKG:1477 ) business as it appears the company...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/ocumension-therapeutics-hkg1477-shift-from-loss-to-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK1191","LENZ","01477","BK4539","BK1574","BK4007"],"gpt_icon":0},{"id":"2555045807","title":"Zhaoke Ophthalmology Ltd. Receives FDA Orphan Drug Designation for Melphalan Targeting Pediatric Retinoblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2555045807","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555045807?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:10","pubTimestamp":1753873837,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Ltd. has announced that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to its proprietary formulation of melphalan for the treatment of pediatric retinoblastoma, a rare pediatric eye cancer. This designation provides a clear regulatory pathway toward the submission of an Investigational New Drug  application in the U.S. If successfully developed and approved, Zhaoke Ophthalmology Ltd. would be eligible for seven years of market exclusivity in the U.S. upon New Drug Application  approval. This exclusivity includes marketing authorization holder status and data exclusivity, offering comprehensive protection in the market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL2KYNbP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06622","BK1583","BK1191"],"gpt_icon":0},{"id":"2555043263","title":"Zhaoke Ophthalmology - US FDA Grants Orphan Drug Designation to Zhaoke's Melphalan","url":"https://stock-news.laohu8.com/highlight/detail?id=2555043263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555043263?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:06","pubTimestamp":1753873599,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TR11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1587","BK1583","06622","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":114,"code":"91000000","status":"200"}]}}